Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

hMaxi-K gene therapy - Sumitomo Pharma America

X
Drug Profile

hMaxi-K gene therapy - Sumitomo Pharma America

Alternative Names: hMaxi-K - Ion Channel Innovations; hMaxi-K; pVAX/hSlo; URO 902

Latest Information Update: 19 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ion Channel Innovations LLC
  • Developer Ion Channel Innovations
  • Class Erectile dysfunction therapies; Gene therapies; Urologics
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Erectile dysfunction; Overactive bladder

Most Recent Events

  • 15 May 2023 Discontinued - Phase-II for Erectile dysfunction in Kuwait (Intracavernous)
  • 15 May 2023 Discontinued - Phase-II for Overactive bladder (Treatment-experienced) in USA (Intravesicular)
  • 28 Apr 2023 Final efficacy and adverse events data from a phase IIa trial in Overactive bladder presented at the 118th Annual Meeting of the American Urological Association (AUA-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top